Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alefacept in Erosive Mucosal Lichen Planus
NCT00135733Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2004
- Primary completion
- Dec 2004
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lichen planus (LP) comparing Alefacept with Placebo (2 arms). Primary endpoints: Changes in pain level and Changes in appearance of lesions. Started Apr 2004; status: terminated.
02
Drugs
alefacept
03
Conditions
lichen planus (LP)
Beyond the preview
Go deeper on NCT00135733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135733.